U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847060) titled 'Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma' on Sept. 23.
Brief Summary: Standard radiotherapy for head and neck squamous cell carcinoma typically requires daily treatments over 6 to 7 weeks. For older adults, these prolonged treatment schedules can cause substantial physical fatigue, travel burden, and treatment interruptions. Hypofractionated radiotherapy delivers higher doses of radiation per session over a shorter total treatment time (approximately 3 weeks), potentially limiting tumor cell regrowth, easing logistical demands on patients, and improving completion rates.
The purpose ...